Brief Title
Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome
Official Title
To Study the Effect of Low Molecular Weight Heparin on the Adenomyosis Patients'Outcome of in Vitro Fertilization-embryo Transplantation
Brief Summary
In assisted reproductive technology, adenomyosis patients are characterized by lower clinical pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study is to explore whether low molecular weight heparin can reduce the abortion rate of adenomyosis patients in frozen thawed embryo transfer cycles.
Study Type
Interventional
Primary Outcome
Early spontaneous abortion rate
Condition
Adenomyosis
Intervention
Low molecular weight heparin
Study Arms / Comparison Groups
Control Group
Description: Adenomyosis patients in control group have normal luteal progesterone support.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
70
Start Date
February 1, 2020
Completion Date
January 31, 2022
Primary Completion Date
January 31, 2022
Eligibility Criteria
Inclusion Criteria: 1. The basal serum level of FSH was less than 10 IU / L 2. Diagnosed with adenomyosis by ultrasound 3. The first frozen thawed embryo transfer cycle, by hormone replacement protocol 4. Transfer at least one high quality frozen embryo; 5. Patients agreed to use low molecular weight heparin after FET, and they were able to sign informed consent in person. Exclusion Criteria: 1. With abnormal karyotype; 2. Accompanied with other uterine diseases: intrauterine adhesion, intramural myoma, moderate to severe endometriosis, congenital uterine malformation, endometrial tuberculosis, thin endometrium < 8mm on the day of transformation, etc; 3. PCOS, RIF patients; 4. There are indications of conventional anticoagulation or antiplatelet therapy, such as antiphospholipid syndrome, autoimmune diseases, coagulation dysfunction, etc; 5. There were contraindications to hormone replacement therapy and low molecular weight heparin; 6. Participating in other clinical studies; 7. Unable to follow-up
Gender
Female
Ages
20 Years - 38 Years
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT04741295
Organization ID
SZ-2021-ADE1
Responsible Party
Principal Investigator
Study Sponsor
Nanjing University
Study Sponsor
, ,
Verification Date
February 2021